A study was conducted to determine the cardiovascular safety of testosterone therapy for treatment of hypogonadism.
Odds of hospitalization higher for men receiving inadequate TTh versus those with normal testosterone concentration while receiving TTh
The FDA has approved Kyzatrex (testosterone undecanoate) for the treatment of primary and secondary hypogonadism in adult males.
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
Efforts to reduce obesity may cut the prevalence of these urological conditions.
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes